Boehringer Ingelheim announced a significant increase in its annual investment in Mexico, focusing on clinical research for 50 new therapies across oncology, cardiometabolic diseases, respiratory conditions, and mental health. This investment aims to strengthen public health through training, technology transfer, and improved pharmacovigilance processes.